Novavax Signs a Clinical Trial Agreement with Nucleus Network to Initiate the Clinical Study Evaluating NVX-CoV2373 Against COVID-19

Shots:

Novavax deploys expertise of the Nucleus to commence P-I clinical study assessing NVX-CoV2373 for the first confirmed COVID-19 vaccines study outside the US. The P-I study is expected to be initiated in mid-May with its preliminary immunogenicity and safety results in July
The study will be the third confirmed global COVID-19 vaccine trial and the first in Australia (at Melbourne and Brisbane clinical sites). Nucleus will assist Novavax to undertake P-I study and fast track NVX-CoV2373 for its early development
Nucleus has applied its highest level of transmission-based precautions within its clinical units including its clinical staff, which makes it an ideal partner for Novavax to rapidly develop a vaccine for COVID-19

Click here to read full press release/ article | Ref: PRNewswire | Image: Nucleus